GlassScriptPhysician profile
Amy G Ali
NPI 1033413422
$2,044.20
in general payments reported to CMS, 2019-2025
30 companies · $335 in 2025
The $335 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $298 · 2020: $27.15 · 2021: $227 · 2022: $342 · 2023: $599 · 2024: $217 · 2025: $335.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,135 · Education: $15.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,134.60 |
| Education | $15.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $437.14 | 2019-2025 | Enbrel, Evenity, Prolia |
| Janssen Biotech, INC. | $186.21 | 2019-2025 | Tremfya, Carvykti |
| Glaxosmithkline, LLC. | $141.55 | 2022-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $141.03 | 2020-2025 | Entyvio, Cuvitru |
| Regeneron Healthcare Solutions, INC. | $119.43 | 2019-2024 | Dupixent |
| Medtronic, INC. | $106.56 | 2023-2024 | Appose Ulc, Minimed 780g |
| Lilly USA, LLC | $97.80 | 2021-2025 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $95.91 | 2022-2025 | Verquvo, Lagevrio |
| Abbvie INC. | $85.82 | 2019-2023 | Rinvoq |
| Pfizer INC. | $72.68 | 2019-2024 | |
| Amarin Pharma, INC. | $58.15 | 2019-2021 | |
| Asensus Surgical, INC. | $55.87 | 2023 | Senhance |
| Exact Sciences Corporation | $53.26 | 2023-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $46.62 | 2021 | |
| Incyte Corporation | $45.95 | 2024-2025 | Jakafi |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $43.39 | 2019 | |
| Sanofi-Aventis U.S. LLC | $38.23 | 2025 | |
| Bioventus LLC | $20.86 | 2022 | |
| Corcept Therapeutics | $19.85 | 2025 | Korlym |
| Lexicon Pharmaceuticals, INC. | $19.77 | 2024 | |
| Inspire Medical Systems, INC. | $19.32 | 2024 | Inspire |
| Seqirus USA INC | $18.10 | 2025 | Fluad, Flucelvax |
| Celgene Corporation | $16.67 | 2023 | Reblozyl |
| Braintree Laboratories, INC. | $16.16 | 2024 | Sutab, Suflave |
| Astrazeneca Pharmaceuticals LP | $15.99 | 2025 | Breztri |
| Mallinckrodt Hospital Products INC. | $15.98 | 2022 | |
| Sandoz INC. | $14.79 | 2023 | Hyrimoz |
| Sun Pharmaceutical Industries INC. | $14.14 | 2021 | |
| Octapharma USA, INC. | $13.84 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.